President Trump plans to impose significant tariffs, potentially up to 200%, on imported pharmaceuticals, a sector largely exempt until now. While aimed at lowering drug costs and boosting domestic manufacturing, experts warn these tariffs could lead to higher drug prices, shortages, and disruptions to complex supply chains. Although the tariffs might be delayed, even lower levies are projected to notably increase U.S. drug costs, disproportionately affecting generic drugs and lower-income households. The policy also seeks to bolster national security by reducing reliance on foreign production, but fully reshoring the entire pharmaceutical supply chain presents substantial cost and logistical challenges.

Source: Live 5 News WCSC